Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Cholinesterase inhibitors reduce aggression, wandering and paranoia in Alzheimer's disease

Cholinesterase inhibitors reduce aggression, wandering and paranoia in Alzheimer's disease

December 10, 2008

INDIANAPOLIS - Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.

Investigators from the Indiana University School of Medicine, the Regenstrief Institute and Wishard Health Services reviewed nine randomized, double-blind, placebo-controlled clinical trials evaluating the effectiveness of three popular cholinesterase inhibitors in managing behavioral and psychological symptoms displayed by patients with Alzheimer's disease.




The researchers report that the trial results indicate cholinesterase inhibitors led to a statistically significant reduction in behavioral and psychological symptoms such as aggression, wandering or paranoia when using the same dosage as administered for improving cognitive impairment.

Nine out of 10 Alzheimer's disease patients display behavioral and psychological symptoms of their disease. The review of the clinical trials revealed that cholinesterase inhibitors are safe, producing no major side effects.

"There is a need for safe alternatives to the anti-psychotic drugs currently used to manage the behavioral and psychological symptoms of Alzheimer's disease. The results of the studies we analyzed are encouraging and suggestive that cholinesterase inhibitors are safe and effective alternatives. However, they are underutilized and typically prescribed for less than three months and for less than 10 percent of patients with Alzheimer's disease. Our findings might provide clinicians with useful data to justify the appropriate use of these medications," said Malaz Boustani, M.D., corresponding author of the Clinical Interventions in Aging paper. Dr. Boustani is assistant professor of medicine at the IU School of Medicine, a Regenstrief Institute research scientist, a research investigator with the IU Center for Aging Research, and chief research officer of the Indianapolis Discovery Network for Dementia.

In Alzheimer's disease there is a decrease in acetylcholine, a chemical in the brain that assists memory, thought and judgment. Cholinesterase inhibitors raise acetylcholine levels. Increased concentrations of acetylcholine in the brain leads to increased communication between nerve cells and may improve or stabilize the symptoms of Alzheimer's disease in the early and moderate stages of progression.

Noll Campbell, PharmD, a clinical pharmacy specialist in geriatric psychiatry with Wishard Health Services and corresponding author of the paper, said that, "This class of medications has already been approved by the Food and Drug Administration to manage symptoms of Alzheimer's-type dementia, although their potential benefits on behavioral symptoms are not frequently identified by many prescribers. Clinical trials of cholinesterase inhibitors have shown benefits in several domains of cognitive function as well as behavioral symptoms associated with dementia, and may improve the management of behavioral problems while reducing the use of more harmful medications that are needed to control behaviors."

Dr. Boustani noted that the vast majority of busy primary care physicians, the doctors who see the majority of patients with Alzheimer's disease, are unaware of the details of the studies analyzed in the Clinical Interventions in Aging paper and he hopes that this new paper, which reviewed the studies, will encourage them to prescribe cholinesterase inhibitors, with its benefits for both cognition and behavior symptoms to their Alzheimer's disease patients.

Indiana University



Related Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News Articles Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News RSS Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News RSS
Benefit of memantine in the treatment of Alzheimer's disease not proven
There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine.

Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimer's
People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

Dementia drugs may put some patients at risk, Queen's study shows
Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.

Drug combinations key in treating neurodegenerative diseases
Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases, Medical College of Georgia researchers say.

Study confirms benefit of combination therapy for Alzheimer's disease
Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities.

Dual treatment of incontinence and dementia associated with functional decline
Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers at Wake Forest University School of Medicine and colleagues.

"Green" method decontaminates deadly nerve agents
Research by two scientists has resulted in an exciting new method for rapidly and safely destroying toxic agents such as chemical weapons and pesticides.

Drugs may not delay onset of dementia; and more
Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself.

Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD
A recently published special issue of the Journal of Alzheimer's Disease contains the contributions from experts in the field of aging, dementia and Alzheimer's disease, who attended the "Fourth Annual Meeting on Brain aging and Dementia: From successful aging to severe dementia."
More Cholinesterase Inhibitors Current Events and Cholinesterase Inhibitors News Articles
  Cholinesterase Inhibitors Offer Modest Benefits.(Brief Article)(Statistical Data Included): An article from: Family Practice News
by Bruce Jancin (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on January 15, 2000. The length of the article is 632 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Cholinesterase Inhibitors Offer Modest Benefits.(Brief Article)(Statistical Data Included)
Author: Bruce Jancin
Publication: Family Practice News (Magazine/Journal)
Date: January 15, 2000
Publisher: International Medical News Group
Volume: 30 Issue: 2 Page: 25

Article Type: Brief Article, Statistical Data Included

Distributed by Thomson...

  Start cholinesterase inhibitor immediately after Alzheimer's Dx. (Improves Cognitive Function).: An article from: Clinical Psychiatry News
by Sally Koch Kubetin (Author)

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on June 1, 2003. The length of the article is 486 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Start cholinesterase inhibitor immediately after Alzheimer's Dx. (Improves Cognitive Function).
Author: Sally Koch Kubetin
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: June 1, 2003
Publisher: International Medical News Group
Volume: 31 Issue: 6 Page: 24(1)

Distributed by Thomson...

  Assessing the value of cholinesterase inhibitors.(GUEST EDITORIAL)(Editorial): An article from: Clinical Psychiatry News
by Thomas Finucane (Author)

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on April 1, 2007. The length of the article is 709 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Assessing the value of cholinesterase inhibitors.(GUEST EDITORIAL)(Editorial)
Author: Thomas Finucane
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: April 1, 2007
Publisher: Thomson Gale
Volume: 35 Issue: 4 Page: 11(1)

Article Type: Editorial

Distributed by Thomson...

  Evidence-based medicine does not support cholinesterase inhibitor use.(Geriatric Psychiatry): An article from: Clinical Psychiatry News
by Doug Brunk (Author)

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on July 1, 2007. The length of the article is 645 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Evidence-based medicine does not support cholinesterase inhibitor use.(Geriatric Psychiatry)
Author: Doug Brunk
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: July 1, 2007
Publisher: Thomson Gale
Volume: 35 Issue: 7 Page: 26(1)

Distributed by Thomson...

  Chronic neuropsychological sequelae of cholinesterase inhibitors in the absence of structural brain damage: two cases of acute poisoning.(Environmental ... from: Environmental Health Perspectives
by Lola Roldan-Tapia (Author), Antonia Leyva (Author), Francisco Laynez (Author), Fernando Sanchez Santed (Author)

This digital document is an article from Environmental Health Perspectives, published by National Institute of Environmental Health Sciences on June 1, 2005. The length of the article is 5824 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Chronic neuropsychological sequelae of cholinesterase inhibitors in the absence of structural brain damage: two cases of acute poisoning.(Environmental Medicine / Case Report)
Author: Lola Roldan-Tapia
Publication: Environmental Health Perspectives (Magazine/Journal)
Date: June 1, 2005
Publisher: National Institute of...

  Start cholinesterase inhibitors early in dementia. (Mild to Moderate Disease).: An article from: Family Practice News
by Miriam E. Tucker (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 2002. The length of the article is 726 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Start cholinesterase inhibitors early in dementia. (Mild to Moderate Disease).
Author: Miriam E. Tucker
Publication: Family Practice News (Magazine/Journal)
Date: October 15, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 20 Page: 13(1)

Distributed by Thomson...

  A review of modern literature on the chemistry and toxicology of organophosphorus inhibitors of cholinesterases,
by N. A Loshadkin (Author)



  Cholinesterase inhibitors underprescribed by all.(Practice Trends): An article from: Clinical Psychiatry News
by Sally Koch Kubetin (Author)

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on February 1, 2005. The length of the article is 404 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Cholinesterase inhibitors underprescribed by all.(Practice Trends)
Author: Sally Koch Kubetin
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: February 1, 2005
Publisher: International Medical News Group
Volume: 33 Issue: 2 Page: 91(1)

Distributed by Thompson...

Cholinesterase Inhibitors in Alzheimer's Disease

Cholinesterase Inhibitors in Alzheimer's Disease
by Gordon Mallarkey (Editor)



  Cholinesterase inhibitors: the earlier, the better. (Mild to Moderate Dementia).(dementia treatment): An article from: Internal Medicine News
by Miriam E. Tucker (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2002. The length of the article is 765 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Cholinesterase inhibitors: the earlier, the better. (Mild to Moderate Dementia).(dementia treatment)
Author: Miriam E. Tucker
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 19 Page: 28(1)

Distributed by Thomson...

© 2009 BrightSurf.com